MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

9.780 +0.230 (+2.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ImmunityBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
IBRX Stock Ignites Retail Frenzy Ahead Of Founder’s Prime-Time TV Blitz — Traders Bets On Saudi Funding And Trump Tailwinds ↗
Founder Patrick Soon-Shiong is set for back-to-back prime-time interviews on Fox News and NewsNation on Friday. 
Via Stocktwits
Topics Government
News headline image
IBRX Stock Rises Pre-Market After ANKTIVA Combo Shows Stronger Bladder Cancer Responses In Phase 2 Trial ↗
The company said it plans to submit a biologics license application by the fourth quarter of 2026. 
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Tread Caution On Nvidia’s China Risk: Why NFLX, WBD, AAPL, CRM, AI, LRMR Are On Traders' Radar Today ↗
Data from Stocktwits showed that retail sentiment on SPY and QQQ diverged. 
Via Stocktwits
Topics Artificial Intelligence ETFs Stocks
News headline image
ImmunityBio Founder Reaffirms Grip As Stock Plunges In Worst Selloff Since 2024 After Massive Rally ↗
The filing comes ahead of ImmunityBio’s participation in the ASCO Genitourinary Cancers Symposium. 
Via Stocktwits
News headline image
IBRX Stock Rallies Into Trump’s Big SOTU Night — Here’s What Traders Think Could Fuel The Next Move ↗
Traders debated whether Trump could reference cancer priorities or FDA reform, with some betting a mention could spark another leg higher for IBRX. 
Via Stocktwits
Topics Economy Government
News headline image
IBRX Stock Surges Past 4-Year Highs: Analyst Sees over 50% Upside After Anktiva’s Blowout Growth ↗
ImmunityBio outlined a three-year plan to position Anktiva as a backbone immunotherapy, advancing more than 30 trials across 10 tumor types. 
Via Stocktwits
News headline image
Stock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700% ↗
On Feb. 23, 2026, investors weighed ANKTIVA’s explosive revenue ramp against ImmunityBio’s deep losses and ambitious global expansion. 
Via The Motley Fool
Topics Stocks
Check out the stocks that are attracting the most attention and driving market activity. ↗
Via Chartmill
News headline image
Why ImmunityBio Stock Is Soaring Again Today ↗
ImmunityBio's stock has roughly quintupled so far in 2026 as the company continues to deliver good news for investors. 
Via The Motley Fool
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 1% Pre-Market ↗
Net product revenue in the fourth quarter surged 431% to $38.3 million, above estimates of $37.8 million, according to Fiscal.ai data 
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’. 
Via Stocktwits
Topics Artificial Intelligence ETFs Government
News headline image
IBRX Stock To Open Week On A High? Chairman Teases Anktiva’s 3-Year Expansion Plans, Hints At Cancer Breakthrough ↗
The chairman pointed to upcoming updates on IL-15’s long-studied role in cancer immunotherapy. 
Via Stocktwits
News headline image
ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts ↗
ImmunityBio announced that it has partnered with Biopharma and Cigalah and hopes to launch Anktiva across the broader Middle East and North Africa (MENA) region over time. 
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Rise Before PCE Report, Likely Tariff Ruling: Why NVDA, TSLA, GOOGL, IBRX, APP, GRAL Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment on QQQ turned bearish amid elevated message volume. 
Via Stocktwits
Topics ETFs Economy Government
News headline image
IBRX Stock Rally Not Over Yet? Chairman Says Trump Diplomacy Led To ‘Amazing Results’ For Cancer Drug ↗
Traders are closely watching positioning, as short interest hit a record 13.7% of the free float amid a jump in retail activity on Stocktwits this week. 
Via Stocktwits
Topics Government
News headline image
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA
As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire... 
Via Finterra
Topics Lawsuit
News headline image
ImmunityBio Announces Partnership To Expand Access To Anktiva Across 30 Countries ↗
The company also announced the establishment of an Irish subsidiary in Dublin to support its distribution and commercialization strategy across Europe. 
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral. 
Via Stocktwits
Topics ETFs Economy Government
News headline image
Why IBRX Stock Became A High-Stakes Showdown Between Shorts And Retail Bulls ↗
The standoff ended when the EU granted conditional approval, sending shares up 42% on Wednesday. 
Via Stocktwits
News headline image
Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer ↗
On Feb. 18, 2026, investors weighed ImmunityBio’s EU bladder cancer win against its long slide since IPO and fresh legal scrutiny. 
Via The Motley Fool
Topics Initial Public Offering Stocks
Here are the top movers in Wednesday's session. ↗
Via Chartmill
News headline image
Why ImmunityBio Stock Is Soaring Today ↗
The biopharma outfit's flagship cancer-fighting drug continues to rack up approvals. 
Via The Motley Fool
Discover the most active stocks in Wednesday's session. ↗
Via Chartmill
Top movers in Wednesday's session ↗
Via Chartmill
News headline image
IBRX Gains 30% On Fresh Approval For Bladder Cancer Drug In EU: Retail, Wall Street Eyes Further Rally ↗
The European Commission granted conditional marketing authorization to ImmunityBio’s Anktiva, implying that it wants more data from the company. 
Via Stocktwits
News headline image
How High Can IBRX Stock Go Now? Here’s What Wall Street Thinks After Saudi Nod For Bladder Cancer Filing ↗
Koyfin data shows an average 12-month target of $11.8, implying a 96% upside from the stock's current levels. 
Via Stocktwits
News headline image
IBRX Stock Jumps 6% Pre-Market On BCG Update In Saudi Arabia – Retail Says Share Price Is ‘Attractive’ ↗
The Saudi Food and Drug Authority encouraged the company to submit a regulatory filing for its recombinant Bacillus Calmette-Guérin, which the company expects to submit within weeks. 
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Lower As AI Disruption Fears Linger: Why AAPL, ZIM, OCUL, NCLH Are On Traders' Radar Today ↗
Wall Street resumed trade after the Presidents’ Day break to find a market still grappling with the ‘AI disruption’ trade. 
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
Anktiva Vs Keytruda: ImmunityBio Exec Chair Slams FDA For Double Standards In Approvals ↗
The comments come as ImmunityBio pushes for broader global access to Anktiva across indications. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story